Adoptive immunotherapy combined chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Issue 5 (June 2016)

• Record Type: Journal Article
• Authors: Qian, Haili; Wang, Haijuan; Guan, Xiuwen; Yi, Zongbi; Ma, Fei
• Is Part Of: Anti-cancer drugs. Volume 27:Issue 5(2016)
• Publication Date: 2016-06
• Subjects: adoptive immunotherapy -- chemotherapy -- meta-analysis -- non-small-cell lung cancer -- radiotherapy; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000346
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : The aim of this study was to compare the efficacies between adoptive immunotherapy combined chemoradiotherapy and chemoradiotherapy alone in patients with non-small-cell lung cancer (NSCLC). The databases PubMed, EMBASE, and Cochrane database were searched to identify eligible clinical trials. Data analyses were carried out using a comprehensive meta-analysis program, version 2 software. A total of seven articles were finally included in the analysis. Meta-analyses showed that compared with chemoradiotherapy alone, adoptive immunotherapy combined with chemoradiotherapy could improve the 2-year overall survival [odds ratio (OR)=2.45, 95% confidence interval (CI): 1.60–3.75, P <0.001], but not 2-year progression-free survival (OR=1.81, 95% CI: 0.61–5.36, P =0.284). Specifically, early (OR=3.32, 95% CI: 1.38–7.95, P <0.01) but not advanced (OR=3.75, 95% CI: 0.96–14.68, P =0.057) NSCLC patients were likely to gain a large benefit from the adoptive immunotherapy. Most of the adoptive immunotherapy-induced adverse effects were self-limited, mainly including fever, shiver, nausea, fatigue, etc. and severe toxicities were not observed. Adoptive immunotherapy combined with chemoradiotherapy can delay the recurrence of NSCLC and improve survival in patients, where the benefits are even more significant in patients with early-stage NSCLC.